AVTX vs. GLYC, VINC, SLGL, OCX, KRON, GANX, OCUP, AADI, DARE, and RVPH
Should you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include GlycoMimetics (GLYC), Vincerx Pharma (VINC), Sol-Gel Technologies (SLGL), OncoCyte (OCX), Kronos Bio (KRON), Gain Therapeutics (GANX), Ocuphire Pharma (OCUP), Aadi Bioscience (AADI), Daré Bioscience (DARE), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "medical" sector.
GlycoMimetics (NASDAQ:GLYC) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability.
GlycoMimetics has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.
In the previous week, GlycoMimetics had 10 more articles in the media than Avalo Therapeutics. MarketBeat recorded 10 mentions for GlycoMimetics and 0 mentions for Avalo Therapeutics. GlycoMimetics' average media sentiment score of 0.00 beat Avalo Therapeutics' score of -0.38 indicating that Avalo Therapeutics is being referred to more favorably in the news media.
GlycoMimetics has a net margin of 0.00% compared to GlycoMimetics' net margin of -1,639.50%. Avalo Therapeutics' return on equity of -88.40% beat GlycoMimetics' return on equity.
Avalo Therapeutics has higher revenue and earnings than GlycoMimetics.
GlycoMimetics currently has a consensus price target of $10.00, indicating a potential upside of 3,785.00%. Given Avalo Therapeutics' higher probable upside, research analysts plainly believe GlycoMimetics is more favorable than Avalo Therapeutics.
GlycoMimetics received 310 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 62.38% of users gave GlycoMimetics an outperform vote while only 31.25% of users gave Avalo Therapeutics an outperform vote.
75.2% of GlycoMimetics shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 8.7% of GlycoMimetics shares are held by insiders. Comparatively, 0.2% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
GlycoMimetics beats Avalo Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Avalo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avalo Therapeutics Competitors List
Related Companies and Tools
